NCT01531894View on ClinicalTrials.gov

Continuation Study of the Oral AKT Inhibitor GSK2110183

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

February 8, 2012

Primary Completion Date

June 20, 2018

Study Completion Date

June 20, 2018

Conditions
Cancer
Interventions
DRUG

GSK2110183 (afuresertib)

Afuresertib is an oral, low nanomolar pan-AKT kinase inhibitor immediate release (IR) 50 mg or 75 mg tablets was to be taken orally with at least 200 mL of water, with or without food, in the morning.

Trial Locations (8)

3004

Novartis Investigative Site, Melbourne

10029

Novartis Investigative Site, New York

10065

Novartis Investigative Site, New York

21231

Novartis Investigative Site, Baltimore

02115

Novartis Investigative Site, Boston

M5G 1Z6

Novartis Investigative Site, Toronto

Unknown

Novartis Investigative Site, Galway

110-744

Novartis Investigative Site, Seoul

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY